top of page

ASCO 2026: Corcept Therapeutics' CEO Joe Belanoff discusses cortisol modulation as an approach to cancer treatment, and the recent approval of Lifyorli for ovarian cancer

  • May 30
  • 1 min read

He describes the science behind cortisol and how Corcept chose ovarian cancer as its first indication because it highly expresses the glucocorticoid receptor. Plus, other cancers this approach might be useful for, and the rationale behind an NDA refiling for Cushing's syndrome.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page